• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Serological and skin‐test diagnosis of birch pollen allergy with recombinantBet vI, the major birch pollen allergen
【24h】

Serological and skin‐test diagnosis of birch pollen allergy with recombinantBet vI, the major birch pollen allergen

机译：Serological and skin‐test diagnosis of birch pollen allergy with recombinantBet vI, the major birch pollen allergen

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

SummaryBackgroundType I allergy represents a severe health problem in industrialized countries where up to 20 of the population suffer froin allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis. leading to death.ObjectiveThe aim of this study was to evaluate recombinantBet vI, the major birch pollen allergen forin vivoandin vitrodiagnosis of birch pollen allergy.MethodsA group of 51 birch pollen allergic patients and eight non‐allergic control individuals were tested for birch pollen allergy by skin‐prick and intradennal testing, comparing commercial birch pollen extracts with recombinantBet vI. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme‐linked immunosorbent assay (ELISA) and immunoblotting.ResultsRecombinantBetv I allowed accuratein vivoandin vitrodiagnosis of tree pollen allergy in 49/51 patients tested. No false positive results were obtained in anyin vitroassay system (ELISA. Westernblot) or by skin testing (skin‐prick, intradermal test) with recombinantBet vI.ConclusionOur results document that recombinantBet vI produced in bacterial expression systems allows accuratein vitroandin vivodiagnosis of birch pollen allergy in>95 of birch pollen allergic p

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号